RESUMEN
Recent developments in molecular genetic testing methods (e.g. next-generation sequencing [NGS]-panels) largely accelerated the process of finding the most appropriate targeted therapeutic intervention for cancer patients based on molecularly targetable genetic alterations. In Hungary, a centralized approval system following the recommendation of the National Molecular Tumor Board was launched for the coordination of all aspects of comprehensive genetic profiling (CGP) including patient selection and therapy reimbursement. AIM: The study aims to evaluate the clinical benefit of CGP in our Comprehensive Cancer Center Methods and patients: CGP was introduced into our routine clinical practice in 2021. An NGS-based large (> 500 genes) gene panel was used for cases where molecular genetic testing was approved by the National Molecular Tumor Board. From 2021 until August 2023 163 cases were tested. The majority of them were ECOG 0-1 patients with advanced-stage diseases, histologically rare cancer, or cancers with unknown primary tumours. RESULTS: Seventy-four cases (74 of 163, 45%) had clinically relevant genetic alterations. In 34 patients, the identified variants represented an indication for an approved therapy (approved by the Hungarian authorities, on-label indication), while in 40 cases the recommended therapy did not have an approved indication in Hungary for certain tumour types, but off-label indication could be recommended. Based on our CGP results, 24 patients (24/163; 14.7%) received targeted therapy. Treatment duration was between 1 and 60 months. In total 14 (14/163; 8.5% of the tested cases) patients had a positive clinical response (objective response or stable disease) and were treated for more than 16 weeks. INTERPRETATION: NGS-based CGP was successfully introduced in our institution and a significant number of patients benefited from comprehensive genetic tests. Our preliminary results can serve as the starting point of Drug Rediscovery Protocol (DRUP) studies.
Asunto(s)
Pruebas Genéticas , Secuenciación de Nucleótidos de Alto Rendimiento , Neoplasias , Medicina de Precisión , Humanos , Hungría , Medicina de Precisión/métodos , Neoplasias/genética , Neoplasias/tratamiento farmacológico , Neoplasias/terapia , Masculino , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Persona de Mediana Edad , Anciano , Adulto , Pruebas Genéticas/métodos , Anciano de 80 o más Años , Adulto Joven , Adolescente , Terapia Molecular Dirigida/métodos , Biomarcadores de Tumor/genéticaRESUMEN
INTRODUCTION: To ensure that all citizens have equal access to high-quality cancer diagnosis and care, the EU4Health Programme, Europe's Beating Cancer Plan, and Horizon Europe's Cancer Mission propose Comprehensive Cancer Infrastructures in every European Union Member State. It is therefore important to establish the basic principles for high-performing cancer networks and a methodology for evaluating their quality and effectiveness. This article describes methods and standards/indicators for network evaluation found in literature, gives a comparative overview of the new OECI European Cancer Network Quality standards, and proposes principles for evaluating the performance of Comprehensive Cancer Networks as a basis for continuous improvement. MATERIALS AND METHODS: We performed a scoping literature review on methods and standards/indicators for care-network evaluation. We then compared the OECI set with literature findings, categorised standards that were similar, reflected on standards that were different, and deduced principles for quality standards for cancer networks. RESULTS: Of 1002 articles identified, 17 reported on evaluation methods and/or (mostly) qualitative indicators. Sixteen studies described indicators/standards for evaluating care networks, critical success factors or desirable outcomes. Of the 54 present OECI standards, 32 had a literature equivalent. No literature equivalent was found for 22 standards, especially on those related to the combination of care and research. The proposed OECI evaluation methods (survey, document review, and interviews) were all reported in the literature. From the conformity of these results, we deduced 8 principles for standards evaluating the effectiveness of Comprehensive Cancer Networks. CONCLUSIONS: Research on the evaluation of the effectiveness of care networks is scarce. Evaluation methods vary and are often single time-point assessments. The OECI set contributes to establishing clear principles and standards to evaluate the effectiveness of Comprehensive Cancer Networks.
Asunto(s)
Neoplasias , Humanos , Neoplasias/diagnóstico , Neoplasias/terapia , Unión EuropeaRESUMEN
BACKGROUND: Chemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this patient population. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, patients were recruited from 196 hospitals and cancer treatment centres in 22 countries. Patients aged 18 years or older, with histologically confirmed, previously untreated, locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, larynx, or oral cavity (unselected for PD-L1 status), an Eastern Cooperative Oncology Group performance status score of 0 or 1, and who could receive chemoradiotherapy were eligible. Patients were randomly assigned (1:1) centrally by means of stratified block randomisation with block size four (stratified by human papillomavirus status, tumour stage, and nodal stage, and done by an interactive response technology system) to receive 10 mg/kg avelumab intravenously every 2 weeks plus chemoradiotherapy (100 mg/m2 cisplatin every 3 weeks plus intensity-modulated radiotherapy with standard fractionation of 70 Gy [35 fractions during 7 weeks]; avelumab group) or placebo plus chemoradiotherapy (placebo group). This was preceded by a single 10 mg/kg avelumab or placebo lead-in dose given 7 days previously and followed by 10 mg/kg avelumab or placebo every 2 weeks maintenance therapy for up to 12 months. The primary endpoint was progression-free survival by investigator assessment per modified Response Evaluation Criteria in Solid Tumors, version 1.1, in all randomly assigned patients. Adverse events were assessed in patients who received at least one dose of avelumab or placebo. This trial is registered with ClinicalTrials.gov, NCT02952586. Enrolment is no longer ongoing, and the trial has been discontinued. FINDINGS: Between Dec 12, 2016, and Jan 29, 2019, from 907 patients screened, 697 patients were randomly assigned to the avelumab group (n=350) or the placebo group (n=347). Median follow-up for progression-free survival was 14·6 months (IQR 8·5-19·6) in the avelumab group and 14·8 months (11·6-18·8) in the placebo group. Median progression-free survival was not reached (95% CI 16·9 months-not estimable) in the avelumab group and not reached (23·0 months-not estimable) in the placebo group (stratified hazard ratio 1·21 [95% CI 0·93-1·57] favouring the placebo group; one-sided p=0·92). The most common grade 3 or worse treatment-related adverse events were neutropenia (57 [16%] of 348 patients in the avelumab group vs 52 [15%] of 344 patients in the placebo group), mucosal inflammation (50 [14%] vs 45 [13%]), dysphagia (49 [14%] vs 47 [14%]), and anaemia (41 [12%] vs 44 [13%]). Serious treatment-related adverse events occurred in 124 (36%) patients in the avelumab group and in 109 (32%) patients in the placebo group. Treatment-related deaths occurred in two (1%) patients in the avelumab group (due to general disorders and site conditions, and vascular rupture) and one (<1%) in the placebo group (due to acute respiratory failure). INTERPRETATION: The primary objective of prolonging progression-free survival with avelumab plus chemoradiotherapy followed by avelumab maintenance in patients with locally advanced squamous cell carcinoma of the head and neck was not met. These findings may help inform the design of future trials investigating the combination of immune checkpoint inhibitors plus CRT. FUNDING: Pfizer and Merck KGaA, Darmstadt, Germany.
Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Recurrencia Local de Neoplasia/tratamiento farmacológico , Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico , Adulto , Anciano , Anticuerpos Monoclonales/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Antígeno B7-H1/antagonistas & inhibidores , Antígeno B7-H1/genética , Quimioradioterapia , Cisplatino/administración & dosificación , Método Doble Ciego , Femenino , Alemania , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/genética , Recurrencia Local de Neoplasia/inmunología , Recurrencia Local de Neoplasia/patología , Placebos/administración & dosificación , Supervivencia sin Progresión , Carcinoma de Células Escamosas de Cabeza y Cuello/genética , Carcinoma de Células Escamosas de Cabeza y Cuello/inmunología , Carcinoma de Células Escamosas de Cabeza y Cuello/patología , Nivel de AtenciónRESUMEN
Recently the prevalence of oligometastatic patients is increasing. A common site of distant spread is the liver. The standard of care is curative surgical resection, however, the resecability rate is only 10-20%. Alternatively, radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) may be used. Stereotactic ablative body radiotherapy (SABRT) makes it possible to deliver curative radiation dose without radiation injury to the healthy liver tissue. We delivered SABRT to three patients with inoperable hepatic metastases. The primary tumors were rectal (2) and lung (1). The dose was 3x20 Gy every other day. We observed one grade 1 side effect. All the metastases showed complete remission and no local recurrence or late side effect occurred during the one year of follow-up. One patient is tumor-free, one has stable disease, in one patient two new hepatic metastases appeared and receives chemo-biological therapy. SABRT of liver metastases is safe and highly effective. It can be expected that in the near future it will become one of the standard treatments of hepatic tumors.
Asunto(s)
Neoplasias Hepáticas/radioterapia , Neoplasias Hepáticas/secundario , Metástasis de la Neoplasia/radioterapia , Radiocirugia , Quimioembolización Terapéutica , Humanos , Resultado del TratamientoRESUMEN
Radiation therapy traditionally plays a major role in the treatment of lymphoproliferative diseases. Diagnostics and treatment of these tumors improved tremendously in the recent decades. Molecular diagnostics is able to discriminate its subtypes more precisely than ever and opens the possibility of the introduction of targeted medicines. Imaging, especially functional imaging now has an established role in forming treatment strategy. Radiation therapy showed substantial technical development too. As a consequence of these, the role, dose and technique of radiotherapy changes instantly. In this short review we discuss situations which clinicians, both hemato-oncologists and radiation oncologist may face day by day. These are: the changing role of radiation therapy in early Hodgkin's disease, including dose and filed size reduction and PET-driven radiation therapy; the use of radiation in advanced Hodgkin's disease; the role of radiation therapy of diffuse large B-cell lymphoma in the light of the use of rituximab; and finally the use of modern radiation therapy techniques like intensity-modulated radiation therapy or particle therapy.
Asunto(s)
Trastornos Linfoproliferativos/radioterapia , Radioterapia , Enfermedad de Hodgkin/radioterapia , Humanos , Linfoma de Células B Grandes Difuso/radioterapia , Radioterapia de Intensidad ModuladaRESUMEN
The majority of cancer patients becomes malnourished during the course of their disease. Malnutrition deteriorates the efficiency of all kinds of oncologic interventions. As a consequence of it, treatment-related toxicity increases, hospital stay is lengthened, chances of cure and survival as well as the quality of life of the patients worsen. Nutritional status therefore influences all aspects of outcome of oncology care. In spite of this the use of nutritional therapy varies across health care providers but its application is far from being sufficient during active oncology interventions as well as rehabilitation and supportive care. It threatens not only the outcome and quality of life of cancer patients but also the success of oncologic treatments which often demand high input of human and financial resources. Meanwhile application of nutritional therapy is legally regulated in Hungary and a very recent update of the European guideline on cancer patient nutrition published in 2017 is available. Moreover, cost effectiveness of nutritional therapy has been proven in a number of studies. In this review we present the basics of nutritional therapy including nutritional screening and evaluation, nutritional plan, the role of nutrition support teams, oral, enteral and parenteral nutrition, the use of different drugs and special nutrients and the follow-up of the patients.
Asunto(s)
Caquexia/terapia , Desnutrición/terapia , Neoplasias/complicaciones , Terapia Nutricional/métodos , Sarcopenia/terapia , Caquexia/etiología , Caquexia/fisiopatología , Humanos , Hungría , Desnutrición/etiología , Desnutrición/fisiopatología , Neoplasias/diagnóstico , Neoplasias/terapia , Calidad de Vida , Medición de Riesgo , Sarcopenia/etiología , Sarcopenia/fisiopatología , Resultado del TratamientoRESUMEN
Pancreatic cancer has one of the worst outcomes among malignant tumors. At the time of diagnosis only 20% of the cases are resectable and 30-50% are locally advanced, when curative intervention cannot be performed. After resection local relapse occurs in 20-60%, and in 30% it is the reason of death. This latter highlights the importance of local control. However, there have been no convincing results with conformal radiation therapy and radiochemotherapy yet. Adjuvant radiochemotherapy has been settled into the routine in the US, but not in Europe and Asia and only sporadic data are available about neoadjuvant radiotherapy. Based on the result of recent studies, conformal radiation therapy does not seem to become part of the standard treatment of locally advanced disease. Radiation resistance, long treatment time and incompatibility with the most advanced chemotherapy regimens may make conformal radiotherapy ineffective. Stereotactic ablative body radiotherapy (SABRT) when a limited target volume is irradiated in few fractions, with high precision and high biological effective dose, is ablative for the tumor and could be a possible solution for this issue. In our report, we describe to our knowledge the first SABRT for locally advanced pancreatic cancer in Hungary and give a short literature review.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Neoadyuvante/métodos , Neoplasias Pancreáticas/patología , Neoplasias Pancreáticas/cirugía , Radiocirugia/métodos , Anciano , Supervivencia sin Enfermedad , Humanos , Hungría , Imagen por Resonancia Magnética/métodos , Masculino , Invasividad Neoplásica/patología , Estadificación de Neoplasias , Neoplasias Pancreáticas/diagnóstico por imagen , Pronóstico , Medición de Riesgo , Análisis de Supervivencia , Insuficiencia del Tratamiento , Resultado del TratamientoRESUMEN
In this paper we present our early experience with a method for the management of respiratory motion in radiotherapy for early-stage lung cancer. Forty-six patients were irradiated with a total dose of 60 Gy. Tumor response on control CT, survival, local and distant progression as well as early and late side effects were registered. Complete and partial remission, stable and progressive disease was 17 (37.0%), 15 (32.6%), 11 (23.9%) and 3 (6.5%). Isolated local recurrence and distant metastasis appeared in 4 (8.7%) and 2 (4.3%) cases, while simultaneous local and distant progression was diagnosed in 3 (6.5%) patients. The probability of 2-year local recurrence-free, progression-free, and overall survival was 76.8%, 64.0%, and 83.2%. Grade 1 (G1) and G2 early side effects occurred at 15 (32.6%) and 3 (6.5%) patients without ≥G3 side effects. G1 and G2 late side effects were observed in 10 (21.7%) and 7 (15.2%) cases. G1-2 post-irradiation fibrosis occurred in 11 (23.9%) cases. Twenty months after the irradiation, G5 respiration failure was developed in one patient. The implemented technique of respiratory motion management for the radiotherapy of early-stage lung cancer resulted in promising local freedom from relapse and survival with favorable side effect profile. Further follow-up is needed to assess longterm side effects and survival results.
Asunto(s)
Neoplasias Pulmonares/radioterapia , Radioterapia/métodos , Terapia Combinada , Humanos , Neoplasias Pulmonares/mortalidad , Estadificación de Neoplasias , Dosificación RadioterapéuticaRESUMEN
The aim of our work is to present the imaging techniques used at the National Institute of Oncology for taking into consideration the breathing motion at radiation therapy treatment planning. Internationally recommended imaging techniques, such as 4D CT, respiratory gating and ITV (Internal Target Volume) definition were examined. The different imaging techniques were analysed regarding the delivered dose during imaging, the required time to adapt the technique, and the necessary equipment. The differences in size of PTVs (Planning Target Volume) due to diverse volume defining methods were compared in 5 cases. For 4D CT breath monitoring is crucial, which requires special equipment. To decrease the relatively high exposure of 4D CT it is possible to scan only a few predefined breathing phases. The possible positions of the tumour can be well approximated with CT scans taken in the inhale maximum, the exhale maximum and in intermediate phase. The intermediate phase can be exchanged with an ordinary CT image set, and the extreme phase CT images can be ensured by given verbal instructions for the patient. This way special gating equipment is not required. Based on these 3 breathing phases an ITV can be defined. Using this ITV definition method the margin between the CTV (Clinical Target Volume) and the PTV can be reduced by 1 cm. Using this imaging protocol PTV can be reduced by 30%. A further 10% PTV reduction can be achieved with respiratory gating. In the routine clinical practice respiratory motion management with a 3-phase CT-imaging protocol the PTV for early-stage lung cancer can be significantly reduced without the use of 4D CT and/or respiratory gating. For special, high precision treatment techniques 4D CT is recommended.
Asunto(s)
Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/fisiopatología , Planificación de la Radioterapia Asistida por Computador/instrumentación , Planificación de la Radioterapia Asistida por Computador/métodos , Mecánica Respiratoria , Tomografía Computarizada por Rayos X , Anciano , Anciano de 80 o más Años , Diseño de Equipo , Femenino , Humanos , Hungría , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/radioterapia , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Dosificación Radioterapéutica , Tomografía Computarizada por Rayos X/instrumentación , Tomografía Computarizada por Rayos X/métodos , Carga TumoralRESUMEN
Prostate cancer is one of the leading cancer types in males in the developed world. Radiotherapy is a major method in the curative treatment of prostate cancer however, up to 30% of the patients experience local relapse. Arachidonic acid metabolites have been shown to have important role in cancer. 12-lipoxygenase (12-LOX) has been proven to significantly influence prostate cancer progression, by apoptosis regulation and by promoting cancer cell survival. In this study we examined whether 12-LOX inhibition may increase radiation sensitivity of prostate cancer cells in vitro and in vivo. Prostate cancer cell lines were treated with 12-LOX inhibitors, different doses of radiation and the combination of 12-LOX inhibitors and radiation. We measured the effect of these treatments through clonogenic survival and apoptosis in vitro and tumor growth in vivo in a tumor xenograft model. 12-LOX inhibition and radiation both increased apoptosis and decreased clonogenic survival of prostate cancer cell lines in vitro. Combined treatment resulted in a supra-additive effect in vitro. In vivo both 12-LOX inhibition and radiotherapy caused delay in growth of the xenograft tumors but the combined treatment resulted in the strongest growth inhibition. The presented data prove that 12-LOX and its metabolite 12(S)-HETE have a major role in prostate cancer cell progression and radiosensitivity. We have shown by different methods in vitro and in vivo that inhibition of 12-LOX activity significantly sensitizes prostate cancer cells to radiation. Therefore we can state that 12-LOX inhibitors are promising compounds to be developed to become a new class of clinical radiation sensitizers in prostate cancer.
Asunto(s)
Apoptosis/efectos de la radiación , Araquidonato 12-Lipooxigenasa/metabolismo , Inhibidores de la Lipooxigenasa/farmacología , Neoplasias de la Próstata/radioterapia , Tolerancia a Radiación/efectos de los fármacos , Receptores Eicosanoides/metabolismo , Línea Celular Tumoral/efectos de la radiación , Supervivencia Celular/efectos de la radiación , Progresión de la Enfermedad , Humanos , Masculino , Neoplasias de la Próstata/patología , Receptores Eicosanoides/efectos de los fármacos , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Background: Several factors can affect overall survival of head and neck cancer (HNC) patients, including characteristics of the cancer disease and response to treatments. However, patients' nutritional status and the effectiveness of medical nutrition therapy (MNT) can also impact overall survival. The primary goal of our research was to collect real-life data on the use of MNT in HNC patients and to specifically investigate the correlation between survival and the duration of uninterrupted (persistent) nutrition. Method: The data of this retrospective, analytical, cohort study was collected from electronic healthcare records from the Hungarian National Health Insurance Fund Management. Overall, 38,675 HNC patients' data of the period between 2012 and 2021 was used. We applied multi-step exclusions to identify patient groups accurately and to avoid biasing factors. Statistical analysis was done by the Kaplan-Meier method, log-rank test, and Cox regression analysis. Results: Throughout the investigated period 16,871 (64%) patients received MNT therapy out of 26,253 newly diagnosed patients (≥18 years). In terms of the persistence of MNT, we divided the patients into three groups (1-3; 4-6; ≥7-month duration of MNT). When comparing these groups, we found that patients receiving long-term (≥7 months) MNT had a significantly longer overall survival (p < 0.0001) than those who received MNT for a shorter duration, both in locally advanced and recurrent/metastatic cases. Conclusion: The main outcome of the study is that there is a positive correlation between the persistence of MNT and the overall survival in HNC patients when nutritional intervention lasts several months. It highlights the responsibility of the specialists during the patient journey to use MNT early and to continue its use for as long as it is beneficial to the patients.
Asunto(s)
Neoplasias de Cabeza y Cuello , Terapia Nutricional , Humanos , Estudios de Cohortes , Estudios Retrospectivos , Neoplasias de Cabeza y Cuello/terapiaRESUMEN
Glioblastoma multiforme has one of the worst prognoses of all cancers. A substantial progression in its treatment has been achieved only eight years ago when a new adjuvant radiochemotherapy regimen containing temozolomid has been introduced to the clinical practice. In this paper we evaluate the treatment results in adjuvant radiochemotherapy of glioblastoma carried out by two neurosurgery and oncology centers in Budapest, Hungary and we compared our results to the data of the reference phase III registration trial of the EORTC/NCIC. We analyzed the data of 210 patients treated for glioblastoma between 2005 and 2013. The primary endpoints of our study were overall survival and side effects. We studied and statistically analyzed the influence of multiple factors on survival. We compared our results with the data of the reference study and other results published in the literature. The median follow-up for the surviving patients in our study was 52 months. The median age of our patients was 58 (18-79) years. Seventy-two women and 138 men have been treated. The median overall survival was 17 (3-96) months, the progression-free survival 11 (3-96) months. The radiochemotherapy phase was completed in 95.2% and the monotherapy phase in 68% of all cases.Univariate analysis showed that age, ECOG status and RPA class had significant influence on survival. In multivariate analysis only RPA class remained statistically significant (RR 1.86, 95% CI 1.14-3.05). The proportion of grade III and worse side effects during the chemoradiation phase was 3.8% and in the monotherapy phase 1.9%. These were hematological side effects only. Serious hematological sequelae occurred nearly exclusively in women. Comparing to the reference study the demographic distribution of the patients was similar in our study but among our patients there were less patients with unfavorable prognosis (ECOG 2 or RPA V), and it resulted in a longer median survival than in the original trial (17 vs. 14.6 months). With this analysis of our patients treated according to the Stupp-protocol for glioblastoma multiforme we validated the results of the original EORTC/NCIC study in a Hungarian patient population. Moreover, this comparison proves that the comprehensive Hungarian neuro-oncology service is not at all inferior when compared to any of the developed countries in Europe.
Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/terapia , Quimioradioterapia Adyuvante , Dacarbazina/análogos & derivados , Glioblastoma/terapia , Procedimientos Neuroquirúrgicos , Adulto , Anciano , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Neoplasias Encefálicas/mortalidad , Quimioradioterapia Adyuvante/efectos adversos , Dacarbazina/administración & dosificación , Dacarbazina/efectos adversos , Dacarbazina/uso terapéutico , Supervivencia sin Enfermedad , Esquema de Medicación , Femenino , Estudios de Seguimiento , Glioblastoma/mortalidad , Humanos , Hungría , Masculino , Persona de Mediana Edad , Dosificación Radioterapéutica , Radioterapia Conformacional/efectos adversos , Estudios Retrospectivos , Factores Sexuales , Análisis de Supervivencia , Temozolomida , Resultado del TratamientoRESUMEN
To improve outcomes, to decrease the rate of local recurrence and development of distant metastases neoadjuvant and adjuvant therapies are employed in cancer patients in forms of radiation, chemo-, endocrine-, targeted-, and immunotherapy or their combination. Nutrition therapy plays important role in all phases of the cancer journey. From neoadjuvant therapy to prehabilitation, early postoperative nutrition, and long-term nutrition care during the adjuvant phase and survivorship determines the survival and quality of life of cancer patients. During the neoadjuvant phase patients may be in poor nutritional condition which can be aggravated by the applied oncological treatment. Beside this apparent threat this period also gives an excellent opportunity to maintain or even improve the nutritional status of the patients by nutrition therapy. After surgery the burdening effects of the operation may jeopardize the execution of adjuvant therapy. After early postoperative feeding a long-term nutrition strategy should be developed for cancer patients in order to avoid nutritional deterioration during the usually lengthy postoperative therapy. In this narrative review we discuss how preoperative nutritional status and medical nutrition therapy influence the results of surgery and after the operation what is the available evidence about nutritional status and outcome and the potentials to influence them by nutrition therapy.
RESUMEN
At the 45th Congress of ESPEN (The European Society for Clinical Nutrition and Metabolism), we presented for the first time the initial results of our 2023 oncology research, in which we revealed positive correlations between the persistence of medical nutrition therapy and overall survival, in head and neck cancer patients. Patients who received longterm nutrition therapy (≥7 months) had a significantly longer survival (p<0.0001) than those who received only short-term nutrition therapy intervention, i.e., for 1-3 months. The aim, methodology and results of the Hungarian research aroused the interest of the congress participants; therefore, we also publish it in Hungarian in the form of a short notice.
Asunto(s)
Neoplasias de Cabeza y Cuello , Terapia Nutricional , Humanos , Estado Nutricional , Neoplasias de Cabeza y Cuello/terapia , Oncología MédicaRESUMEN
Over the past decade, significant progress has been made in the management of rectal cancer. Advances in surgical technique and adjuvant therapies have led to significant improvements in outcome for some patients. The advances in preoperative therapies have led to the need for an accurate preoperative staging technique to select those patients who are expected to benefit from these interventions without subjecting others to unnecessary treatment. Performing neoadjuvant therapy knowledge of the relationship of the tumor to the circumferential resection margin is of importance. In Hungary, respecting European guidelines, the high resolution magnetic resonance imaging is mandatory in the staging of rectal cancer, and in early rectal cancer transrectal endosonography has a complementary role. The current role of multidetector computer tomography is for detecting distant metastasis and in local tumor staging of advanced cancers.
Asunto(s)
Ganglios Linfáticos/patología , Imagen por Resonancia Magnética , Neoplasias del Recto/diagnóstico , Neoplasias del Recto/terapia , Recto/patología , Endosonografía , Humanos , Hungría , Metástasis Linfática/diagnóstico , Imagen por Resonancia Magnética/métodos , Terapia Neoadyuvante/métodos , Estadificación de Neoplasias , Neoplasias Peritoneales/diagnóstico , Neoplasias Peritoneales/secundario , Neoplasias del Recto/diagnóstico por imagen , Neoplasias del Recto/patología , Tomografía Computarizada por Rayos X , Neoplasias Vasculares/diagnóstico , Neoplasias Vasculares/secundarioRESUMEN
During oncological treatments, body mass index (BMI) and weight loss (WL) are important prognostic factors, but can be influenced by nutrition therapy. The aim of the study was to collect data on BMI and WL of patients with lung cancer and on the nutritional therapy influencing malnutrition. In our multicenter, retrospective study involving 1616 patients, data were collected using a questionnaire with 51 questions, and statistical analysis was performed with descriptive, and multivariate analysis methods with IBM SPSS 20 software. According to the method of Martin, based on BMI and WL, patients were ranked on a scale of 0 to 4 (grade 0 24.9%; grade 1 20.7%; grade 2 14.9%; grade 3 22.4%; grade 4 17.0%). Based on this data low BMI and WL may affect survival in 75.1%. In contrast, only 37.6% of patients received nutritional therapy, based on 47 different strategies. The data substituted into the prognostic matrix highlights that weight loss may shorten patients' survival. The 47 strategies indicate that the use of nutritional therapy is inconsistent throughout this patient cohort.
Asunto(s)
Neoplasias Pulmonares , Pérdida de Peso , Índice de Masa Corporal , Humanos , Hungría , Neoplasias Pulmonares/terapia , Estudios RetrospectivosRESUMEN
Since the introduction of next-generation sequencing, the frequency of germline pathogenic TP53 variants and the number of cases with unusual clinical presentations have been increasing. This has led to the expansion of the classical Li-Fraumeni syndrome concept to a wider cancer predisposition syndrome designated as the Li-Fraumeni spectrum. Here, we present a case with a malignant, metastatic perivascular epithelioid cell tumor (PEComa) of the thigh muscle and a sinonasal carcinoma harboring a novel TP53 germline splice mutation (NM_000546.5:c.97-2A>C). The classical presentation of LFS in the long-since deceased mother and the presence of a germline TP53 variant in the proband suggested a possible familial TP53-related condition. Complex pathological, molecular, and clinical genetic analyses (whole exome sequencing of germline variants, multigene panel sequencing of tumor DNA, Sanger validation, an in vitro functional test on splicing effect, 3D protein modeling, p53 immunohistochemistry, and pedigree analysis) were performed. The in vitro characterization of the splice mutation supported the pathogenic effect that resulted in exon skipping. A locus-specific loss of heterozygosity in the PEComa but not in the sinonasal carcinoma was identified, suggesting the causative role of the splice mutation in the PEComa pathogenesis, because we excluded known pathogenetic pathways characteristic to PEComas (TSC1/2, TFE3, RAD51B). However, the second hit affecting TP53 in the molecular pathogenesis of the sinonasal carcinoma was not identified. Although PEComa has been reported previously in two patients with Li-Fraumeni syndrome, to the best of our knowledge, this is the first report suggesting a relationship between the aberrant TP53 variant and PEComa.
RESUMEN
BACKGROUND: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. METHODS: Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. RESULTS: A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. CONCLUSION: Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.
Asunto(s)
COVID-19 , Neoplasias , COVID-19/epidemiología , COVID-19/prevención & control , Vacunas contra la COVID-19 , Humanos , Lenguaje , VacunaciónRESUMEN
INTRODUCTION: Primary mediastinal lymphoma (PMBCL) is an aggressive diffuse large B-cell lymphoma entity. It is a rare disease with specific clinical symptoms. The tumor is predominantly localized in the mediastinum but grows rapidly and infiltrates the surrounding tissues and organs. Two thirds of the patients are young females. Previous studies showed that third generation treatments are more effective than former standard cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP) regimens. AIM: Authors' goal was to assess whether adding the anti-CD20 monoclonal antibody, rituximab to the standard CHOP regimen improves the efficacy of the treatment compared to their previous results with CHOP and third generation chemotherapy regimens. METHODS: Between October, 2002 and December, 2004 they have started the rituximab-CHOP (R-CHOP) treatment of 20 newly diagnosed, previously untreated PMBCL patients. Results were compared to the data of 24 patients receiving CHOP (n = 9) or procarbazin-prednisolone-doxorubicin-cyclophosphamide-etoposide-cytosin-arabinoside-bleomycin-vincristin-methotrexate (ProMACE-CytaBOM) (n = 15) treatment in the past. RESULTS: During an average follow-up of 64.6 months, the 5-year overall survival (OS) rate was significantly higher in the R-CHOP group compared to the CHOP treatment (79.4% vs. 33.3%; p = 0.026). However, due to the low number of cases, significant statistical difference could not be demonstrated in the 5-year event-free survival (EFS: 70.0% vs. 33.3%; p>0.05), disease-free survival (DFS: 70.0% vs. 33.3%; p>0.05) and relapse-free survival rate (RFS: 93.0% vs. 100%; p> 0.05), despite of the remarkable numeric difference. When comparing the 5-year survival rates of R-CHOP and ProMACE-CytaBOM treatments, the results were very similar without any significant statistical difference between the two types of treatment (OS: 79.4% vs. 80%; EFS: 70.0% vs. 60.0%; DFS: 70.0% vs. 60.0%; RFS: 93.0% vs. 82.0%; p> 0.05 in all cases). With adding rituximab to CHOP treatment, which was previously considered an insufficient treatment on its own, authors have obtained as good results in treating PMBCL as with third generation regimens. Patients have received the R-CHOP treatments without major side effects and mainly as out-patients. CONCLUSIONS: Standard R-CHOP treatment could therefore replace the more toxic third generation regimens in PMBCL as well. The data are comparable with those reported in the international literature.